Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD

Blood (2013) 122 (21): 63.

https://doi.org/10.1182/blood.V122.21.63.63

Published: 2013

Journal Articles

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Alessandra Cesano, M.D., Ph.D., Santosh Putta, Ph.D., Kavita Mathi, MD, David B. Rosen, PhD, Urte Gayko, Ph.D., Rachael E. Hawtin, Ph.D., Larry D Cripe, MD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Elisabeth Paietta, Ph.D.

Blood (2011) 118 (21): 2512.

https://doi.org/10.1182/blood.V118.21.2512.2512

Published: 2011

Journal Articles

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Elisabeth Paietta, Ph.D., Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark Litzow, M.D., Anthony H. Goldstone, FRCP, FRCPath, Peter H. Wiernik, MD

Blood (2008) 112 (11): 1907.

https://doi.org/10.1182/blood.V112.11.1907.1907

Published: 2008

Journal Articles

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Robert E. Gallagher, MD, Esther L. Schachter-Tokarz, B.A., Barry K. Moser, Ph.D., Dorie Sher, B.A., Elisabeth Paietta, Ph.D., Martin S. Tallman, M.D., Clara D. Bloomfield, M.D., Bayard L. Powell, M.D., Richard A. Larson, M.D., Frederick R. Appelbaum, M.D., Cheryl L. Willman, M.D., Richard C. Harvey, Ph.D., Wendy Stock, M.D.

Blood (2006) 108 (11): 2342.

https://doi.org/10.1182/blood.V108.11.2342.2342

Published: 2006

Journal Articles

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Jacob M. Rowe, MD, Xiaochun Li, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Charles A. Schiffer, MD, Peter H. Wiernik, MD, Mark R. Litzow, MD, Larry D. Cripe, MD, Hillard M. Lazarus, MD, Elisabeth Paietta, Ph.D, Gordon W. Dewald, MD, Howard J. Weinstein, MD, Angela K. Ogden, MD, William G. Woods, MD, Lois Shepherd, MD, James H. Feusner, MD, Clara D. Bloomfield, MD, Martin S. Tallman, MD

Blood (2005) 106 (11): 546.

https://doi.org/10.1182/blood.V106.11.546.546

Published: 2005

NARROW

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Email alerts

ASH Publications

American Society of Hematology

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only